Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control

Arena Pharmaceuticals, Inc.

announced today the filing of a Marketing Authorization Application with the European Medicines Agency (

) for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in patients who are obese (BMI >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition. Arena expects the EMA will accept the filing later this month and confirm the filing is sufficiently complete to permit a substantive review.